Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ReciBioPharm is a leading Contract Development and Manufacturing Organization (CDMO) specializing in advanced therapy medicinal products (ATMPs) and biologics. As the dedicated biologics division of the Recipharm group, the company provides end-to-end services for complex modalities including mRNA, viral vectors, plasmid DNA, and live biotherapeutic products. It was established through the strategic integration of specialized entities such as Arranta Bio, Vibalogics, and GenIbet to address the growing demand for outsourced manufacturing in the cell and gene therapy sectors. ReciBioPharm operates a global network of state-of-the-art facilities in the United States and Europe, supporting clients from early-stage process development through to commercial-scale production. The company's capabilities include comprehensive analytical testing, process optimization, and sterile fill-finish services.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ReciPharm Advanced Bio.